OMER · Omeros Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $587.0K | - | - | - | - | - | - | - | - | - |
| Gross Profit | ($587.0K) | - | - | - | - | - | - | - | - | - |
| R&D | $13.36M | - | $15.99M | $22.01M | $23.85M | - | $24.08M | $45.35M | $26.77M | - |
| SG&A | $13.37M | - | $10.40M | $10.35M | $11.12M | - | $11.32M | $13.81M | $12.26M | - |
| Total Operating Expenses | $27.31M | - | $26.39M | $32.35M | $34.97M | - | $35.41M | $59.16M | $39.03M | - |
| D&A | $239.0K | - | $200.0K | $200.0K | $289.0K | - | $200.0K | $300.0K | $204.0K | - |
| Operating Income | ($17.42M) | - | ($26.39M) | ($32.35M) | ($34.97M) | - | ($35.41M) | ($59.16M) | ($39.03M) | - |
| Interest Expense | $5.89M | - | $4.05M | $15.0K | $8.23M | - | $4.05M | $9.21M | $8.23M | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | $56.06M | - | ($30.92M) | ($25.42M) | ($33.46M) | - | ($32.23M) | ($56.04M) | ($37.18M) | - |
| EPS - Basic | $0.78 | - | ($0.47) | ($0.43) | ($0.58) | - | ($0.56) | ($0.97) | ($0.63) | - |
| EPS - Diluted | $0.62 | - | ($0.56) | ($0.97) | ($0.63) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.91M | $9.66M | $2.40M | $1.90M | $4.26M | $3.40M | $1.52M | $2.12M | $1.83M | $7.11M |
| Accounts Receivable | $6.75M | $10.92M | $6.91M | $6.28M | $7.08M | $7.74M | $6.39M | $8.08M | $7.64M | $8.10M |
| Inventory | $0 | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.37M | $4.76M | $12.50M | $8.84M | $4.41M | $5.91M | $7.72M | $6.50M | $6.18M | $7.71M |
| Current Assets | $180.35M | $215.67M | $71.81M | $69.65M | $96.18M | $134.12M | $164.92M | $202.93M | $280.96M | $217.90M |
| Total Assets | $286.17M | $325.63M | $185.71M | $200.57M | $235.16M | $277.08M | $313.33M | $356.31M | $437.49M | $378.27M |
| Current Liabilities | $59.44M | $78.06M | $80.76M | $85.50M | $83.22M | $79.53M | $55.62M | $59.48M | $59.06M | $53.32M |
| Long-term Debt | - | $87.90M | $154.94M | $154.94M | $164.94M | $164.94M | $164.94M | $164.94M | - | $213.16M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($63.33M) | ($121.23M) | ($220.48M) | ($228.69M) | ($213.55M) | ($182.61M) | ($154.17M) | ($124.60M) | ($71.33M) | ($24.98M) |
| Retained Earnings | ($857.63M) | ($913.70M) | ($1.00B) | ($969.23M) | ($943.80M) | ($910.35M) | ($878.99M) | ($846.75M) | ($790.71M) | ($753.53M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($14.51M) | - | - | - | ($35.84M) | - | - | - | ($41.78M) | - |
| Investing Cash Flow | $28.73M | - | - | - | $38.54M | - | - | - | ($61.92M) | - |
| Financing Cash Flow | ($21.98M) | - | - | - | ($1.84M) | - | - | - | $98.43M | - |
| CapEx | $0 | - | - | - | $41.0K | - | - | - | $58.0K | - |
| Free Cash Flow | ($14.51M) | - | - | - | ($35.88M) | - | - | - | ($41.84M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | -0.26 | - | - | - | 1.07 | - | - | - | 1.13 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | - | - |
| Return on assets | 19.6% | - | -16.6% | -12.7% | -14.2% | - | -10.3% | -15.7% | -8.5% | - |
| Return on equity | -88.5% | - | 14.0% | 11.1% | 15.7% | - | 20.9% | 45.0% | 52.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.03 | 2.76 | 0.89 | 0.81 | 1.16 | 1.69 | 2.96 | 3.41 | 4.76 | 4.09 |
| Quick ratio | 3.03 | 2.76 | 0.89 | 0.81 | 1.16 | 1.69 | 2.96 | 3.41 | 4.76 | 4.09 |
| Cash ratio | 0.03 | 0.12 | 0.03 | 0.02 | 0.05 | 0.04 | 0.03 | 0.04 | 0.03 | 0.13 |
| Leverage | ||||||||||
| Debt / Equity | - | -0.73 | -0.70 | -0.68 | -0.77 | -0.90 | -1.07 | -1.32 | - | -8.53 |
| Debt / Assets | - | 0.27 | 0.83 | 0.77 | 0.70 | 0.60 | 0.53 | 0.46 | - | 0.56 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -3.0x | - | -6.5x | -2156.9x | -4.2x | - | -8.7x | -6.4x | -4.7x | - |
| Equity multiplier | -4.52 | -2.69 | -0.84 | -0.88 | -1.10 | -1.52 | -2.03 | -2.86 | -6.13 | -15.14 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 0d | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 3337d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 17.0x | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 50.2% | - | 25.5% | 45.3% | 10.4% | - | 26.5% | -44.6% | -9.3% | - |
| Net income growth (YoY) | - | - | 4.1% | 54.6% | 10.0% | - | 14.6% | -50.3% | -10.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 59.6% | - | - | - | 14.2% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 70.3% | 33.6% | -43.0% | -83.5% | -199.4% | -630.9% | -1005.0% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Product / service
$900.0K totalPDE7$900.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing OMEROS CORP against the 5 most active filers in the same SIC group.